NormanWolmarkMD

General Surgery • Pittsburgh, PA

Breast, Surgical Oncology (Other than Breast)

Professor of Surgery University of Pittsburgh, Chair NSABP, PI NRG Oncology,

Join to view full profile

Dr. Wolmark is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wolmark's full profile

Already have an account?

Office
2 Allegheny Center #1200
University of Pittsburgh
Pittsburgh, PA 15212
Phone+1 412-339-5322

Fax+1 412-697-4872
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 1978 - 1979
Clinical Center at the National Institutes of HealthFellowship, Complex General Surgical Oncology, 1976 - 1978
UPMC Medical Education (Pittsburgh)Residency, Surgery, 1974 - 1976
McGill University Faculty of MedicineClass of 1970

Certifications & Licensure

NY State Medical License 1978 - Present
PA State Medical License 1973 - 2024
MD State Medical License 1976 - 1993
DC State Medical License 1977 - 1979

Awards, Honors, & Recognition

Fellow (FRCSC) Royal College of Physicians and Surgeons of Canada, 1976
Fellow (FACS) American College of Surgeons

Clinical Trials

Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer Start of enrollment: 1998 Jun 01
Completed
Phase 2
Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes Start of enrollment: 1999 Mar 01
Completed
Phase 3
Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer Start of enrollment: 1999 May 01
Completed
Phase 3
Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women Start of enrollment: 1999 May 01
Completed
Phase 3
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 Start of enrollment: 2000 Feb 01
Completed
Phase 3
Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer Start of enrollment: 2001 Jan 01
Completed
Phase 3
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen Start of enrollment: 2001 May 01
Completed
Phase 3
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer Start of enrollment: 2003 Jan 01
Completed
Phase 2
Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Start of enrollment: 2003 Jan 01
Completed
Phase 3
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer Start of enrollment: 2004 Jul 01
Unknown status
Phase 3
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer Start of enrollment: 2004 May 01
Completed
Phase 3
Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer Start of enrollment: 2004 Jul 01
Terminated
Phase 3
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer Start of enrollment: 2007 Jan 01
Completed
Not Applicable
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Start of enrollment: 2004 Oct 01
Completed
Phase 3
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Start of enrollment: 2004 Sep 15
Completed
Phase 3
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer Start of enrollment: 2005 Apr 01
Completed
Phase 2
Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer Start of enrollment: 2006 Jan 01
Terminated
Phase 3
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon Start of enrollment: 2006 Mar 01
Terminated
Phase 2
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery Start of enrollment: 2006 Mar 01
Completed
Phase 2
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum Start of enrollment: 2006 Jun 01
Withdrawn
Phase 2
Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer Start of enrollment: 2006 Aug 01
Completed
Phase 2
A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer Start of enrollment: 2001 Nov 01
Completed
Phase 2
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer Start of enrollment: 2006 Aug 01
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery Start of enrollment: 2006 Nov 01
Unknown status
Phase 3
Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers Start of enrollment: 2006 Nov 01
Completed
Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer Start of enrollment: 1989 Jul 01
Completed
Phase 3
Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery Start of enrollment: 1984 Mar 01
Completed
Phase 3
Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery Start of enrollment: 1977 Sep 01
Completed
Phase 3
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer Start of enrollment: 2007 Jul 01
Unknown status
Phase 3
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab Start of enrollment: 2008 Apr 01
Terminated
Phase 3
A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver Start of enrollment: 2010 Jan 01
Completed
Phase 2
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer Start of enrollment: 2009 May 01
Completed
Phase 3
Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45
Withdrawn
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer Start of enrollment: 2010 Oct 01
Completed
Phase 2
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery Start of enrollment: 2010 Aug 01
Terminated
Phase 3
Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32 Start of enrollment: 2011 Jul 01
Unknown status
Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer Start of enrollment: 2011 Aug 01
Completed
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer Start of enrollment: 2011 May 01
Completed
Phase 1
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Start of enrollment: 2012 Apr 01
Active, not recruiting
Phase 3
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 2
NSABP Patient Registry and Biospecimen Profiling Repository Start of enrollment: 2013 Feb 01
Completed
NSABP Biospecimen Discovery Project Start of enrollment: 2013 Jul 01
Active, not recruiting
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer Start of enrollment: 2014 Nov 01
Withdrawn
Phase 2
Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer Start of enrollment: 2013 Oct 01
Withdrawn
Phase 1, Phase 2
A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 1, Phase 2
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer Start of enrollment: 2016 Jun 01
Terminated
Phase 3
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Start of enrollment: 2017 Jul 31
Completed
Phase 2
Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer Start of enrollment: 2018 May 14
Completed
Phase 2
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo Start of enrollment: 2017 Dec 19
Active, not recruiting
Phase 3
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status Start of enrollment: 2018 May 18
Active, not recruiting
Phase 2
Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients Start of enrollment: 2019 May 15
Active, not recruiting
Phase 1
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer Start of enrollment: 2018 Oct 22
Completed
Phase 2
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer Start of enrollment: 2019 May 03
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C Lucas, Charles E Geyer, Louis Fehrenbacher, Stephen K Chia, Adam M Brufsky, Janice ...> ;Clinical Cancer Research. 2024 Feb 20
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]).
Geyer, C., Blum, J., Yothers, G., Asmar, L., Flynn, P., Robert, N., Hopkins, J., O'Shaughnessy, J., Rastogi, P., Puhalla, S., Hilton, C., Dang, C., Gómez, H., Vukelja,...> ;Journal of Clinical Oncology. 2024 Feb 9
Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.
Lujia Chen, Ying Wang, Chunhui Cai, Ying Ding, Rim S Kim, Corey Lipchik, Patrick G Gavin, Greg Yothers, Carmen J Allegra, Nicholas J Petrelli, Jennifer Marie Suga, Jud...> ;Journal of Clinical Oncology. 2024 Feb 5
5 citations
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Eleftherios P Mamounas, Hanna Bandos, Priya Rastogi, Barry C Lembersky, Jong-Hyeon Jeong, Charles E Geyer Jr, Louis Fehrenbacher, Stephen K Chia, Adam M Brufsky, Janic...> ;Journal of the National Cancer Institute. 2023 Nov 8
12 citations
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epider...
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E Geyer Jr, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine Piccart, Herve Bo...> ;Journal of Clinical Oncology. 2023 Jun 1
7 citations
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Can...
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, Marion T van Mackelenbergh, Michael Untch, Priya Rastogi, Luca Gianni, Andreas Schneeweiss, Pierfranco Conte, Martine...> ;Journal of Clinical Oncology. 2023 Jun 1
3 citations
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41.
Priya Rastogi, Gong Tang, Saima Hassan, Charles E Geyer Jr, Catherine A Azar, Gustav C Magrinat, J Marie Suga, Harry D Bear, Luis Baez-Diaz, Shakir Sarwar, Jean-Franco...> ;Breast Cancer Research and Treatment. 2023 Jun 1
5 citations
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast...
Carsten Denkert, Chiara Lambertini, Peter A Fasching, Katherine L Pogue-Geile, Max S Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios...> ;Clinical Cancer Research. 2023 Apr 14
2 citations
Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.
Azadeh Nasrazadani, Yujia Li, Yusi Fang, Osama Shah, Jennifer M Atkinson, Joanna S Lee, Priscilla F McAuliffe, Rohit Bhargava, George Tseng, Adrian V Lee, Peter C Luca...> ;British Journal of Cancer. 2023 Apr 1
Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial.
Pooja P Advani, Kathryn J Ruddy, Joerg Herrmann, Jordan C Ray, Emily C Craver, Greg Yothers, Reena S Cecchini, Corey Lipchik, Huichen Feng, Priya Rastogi, Eleftherios ...> ;Frontiers in Oncology. 2023 Jan 1
10 citations
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
Sibylle Loibl, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas, Charles E Geyer Jr, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas...> ;NPJ Breast Cancer. 2022 Sep 19
1 citations
Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer...
Charles E Geyer Jr, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux, Louis Fehrenbacher, Patrick J Ward, Jonathan Polikoff, Adam M Brufsky, Louise Provenc...> ;Breast Cancer Research and Treatment. 2022 Jun 1
4 citations
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-3...
Charles E Geyer Jr, Hanna Bandos, Priya Rastogi, Samuel A Jacobs, André Robidoux, Louis Fehrenbacher, Patrick J Ward, Jonathan Polikoff, Adam M Brufsky, Louise Provenc...> ;Breast Cancer Research and Treatment. 2022 Jun 1
66 citations
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow...
C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark, J O'Shaughnessy, D Maag, M Untch, M Golshan, J Ponce Lorenzo, O Metzger, M Dunbar, W F Symmans, P Rastogi, J H Soh...> ;Annals of Oncology. 2022 Apr 1
1 citations
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.
Patricia A Ganz, Hanna Bandos, Charles E Geyer Jr, André Robidoux, Alexander H G Paterson, Jonathan Polikoff, Luis Baez-Diaz, Adam M Brufsky, Louis Fehrenbacher, Ann W...> ;Breast Cancer Research and Treatment. 2022 Feb 1
1 citations
Patient-specific meta-analysis of 12-gene colon cancer recurrence score validation studies for recurrence risk assessment after surgery with or without 5FU and oxalipl...
Greg Yothers, Alan P Venook, Eiji Oki, Donna Niedzwiecki, Yan Lin, Michael R Crager, Calvin Chao, Frederick L Baehner, Norman Wolmark, Takayuki Yoshino> ;Journal of Gastrointestinal Oncology. 2022 Feb 1
60 citations
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal J Burstein, Richard Greil, Peter Fox, Antonio C Wolff, Arlene Chan, Eric P Winer, Georg Pfeiler, Kath...> ;Journal of Clinical Oncology. 2022 Jan 20
11 citations
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness.
Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter Ansell, Mark A. Watson, Junu Bae, Mathew Cherian, Joyce O'Shaughnessy, Michael Untch, Hope S. Rugo, Jens Huobe...> ;NPJ Breast Cancer. 2021 Nov 11
5 citations
Re-Evaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials
Jun Yin, Mohamed E. Salem, Jesse G. Dixon, Zhaohui Jin, Romain Cohen, Aimery de Gramont, Eric Van Cutsem, Julien Taieb, Steven R. Alberts, Norman Wolmark, Hans-Joachim...> ;Journal of the National Cancer Institute. 2021 Sep 10
19 citations
Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database.
Zhaohui Jin, Jesse G. Dixon, Jack Fiskum, Hiral D. Parekh, Frank A. Sinicrope, Greg Yothers, Carmen J. Allegra, Norman Wolmark, Daniel G. Haller, Hans-Joachim Schmoll,...> ;Journal of the National Cancer Institute. 2021 Aug 18
112 citations
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Rosie Bradley, Jeremy P Braybrooke, Richard Gray, Robert Kerrin Hills, Z Liu, Richard Peto, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn W. Taylor, S...> ;The Lancet. Oncology. 2021 Aug 1
72 citations
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Osama E. Rahma, Greg Yothers, Theodore S. Hong, Marcia M. Russell, Y. Nancy You, William Parker, Samuel A. Jacobs, Linda H. Colangelo, Peter C. Lucas, Marc J. Gollub, ...> ;JAMA Oncology. 2021 Aug 1
566 citations
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew Tutt, Judy Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmaña, Susa...> ;The New England Journal of Medicine. 2021 Jun 3
7 citations
MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.
Alexander H.G. Paterson, Peter C. Lucas, Stewart J. Anderson, Eleftherios P. Mamounas, Adam Brufsky, Luis Baez-Diaz, Karen M. King, Thomas E. Lad, André Robidoux, Mela...> ;JNCI Cancer Spectrum. 2021 May 28
3 citations
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab.
Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher, Charles E. Geyer, Priya Rastogi, John Crown, M. Thirlwell, David M. Ellison, Jean Francois Boileau, Patrick J....> ;NPJ Breast Cancer. 2021 May 20
Join now to see all

Journal Articles

21-Gene Assay as Predictor of Chemotherapy Benefit in HER2-Negative Breast Cancer
Eleftherios P Mamounas, Frederick L Baehner, Norman Wolmark, D Lawrence Wickerham, Nature

Lectures

Chemotherapy Foundation Symposium
Mount Sinai School of Medicine, New York, New York - 11/6/2012

Press Mentions

Dan Hayes Witnessed Cancer History, Now He Is Documenting It in a PodcastJune 4th, 2021
Walter Lawrence, 95, Reflects on the National Cancer Act, Medicine, Social Justice, COVID-19, and Richmond’s Vanishing MonumentsAugust 6th, 2020
21-Gene Recurrence Score for Prognosis and Prediction of Taxane Benefit After Adjuvant Chemotherapy plus Endocrine Therapy: Results from NSABP B-28/NRG OncologyNovember 11th, 2019
Join now to see all